primary antibodies against alpha fetoprotein  (Proteintech)

Journal: bioRxiv

Article Title: Senolytic Treatment Reduces Cell Senescence and Necroptosis in Sod1 Knockout Mice that is Associated with Reduced Inflammation and Hepatocellular Carcinoma

doi: 10.1101/2022.05.15.491998

Figure Lengend Snippet: Liver cancer is reduced in Sod1KO mice treated with D+Q. Panel A shows the liver weight normalized to body weight. Panel B shows α-fetoprotein (AFP) levels in the serum expressed as ng/mL. Panel C shows the heat map for the RT² Profiler™ PCR Arrays of 84 genes related to liver cancer for normal liver tissue from WT and Sod1KO mice treated with vehicle or D+Q as well as tumor tissue from Sod1KO mice treated with vehicle. Transcript levels greater than the mean are shaded in red and those lower than the mean are shaded in blue. Panel D shows the quantification of the fold change in mRNA levels for four genes (Myc, Tgfbr2, Socs3 and Cdkn2a) that were significantly increased in normal tissue from Sod1KO mice treated with vehicle. The data were obtained from 4 to 6 mice per group and are expressed as mean ± SEM. The data in the graphs in Panels A , B and D are shown as follows: non-tumor tissue from WT mice treated with vehicle (white bars), WT mice treated with D+Q (blue bars), Sod1KO treated with vehicle (red bars), and Sod1KO mice treated with D+Q (green bars) and tumor tissue from Sod1KO mice treated with vehicle (red bars with strips). (ANOVA, **** P < 0.0001, *** P ≤ 0.0005, ** P ≤ 0.005, * P≤ 0.05). Panel E graphically shows the number of WT and Sod1KO mice treated with vehicle or D+Q that showed the presence (red) or absence of hepatocellular carcinoma tumors (green). None of the WT mice treated with vehicle (n=15) or D+Q (n=11) showed the presence of tumors while seven of Sod1KO mice treated with vehicle (n=11) and one of the Sod1KO mice treated with D+Q (n=13) showed the presence of tumors.

Article Snippet: Liver sections were then permeabilized, blocked, and incubated with primary antibodies against glypican-3 or α-fetoprotein (Thermofisher Scientific, Waltham, MA).

Techniques:

Journal: Scientific Reports

Article Title: Wharton’s jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni -induced liver fibrosis

doi: 10.1038/srep21005

Figure Lengend Snippet: Photomicrographs of immunohistochemical staining (immunostain, DAB, X400) of ( A ) human alpha fetoprotein (AFP), ( B ) cytokeratin-18 (CK-18), ( C ) Hep par-1, ( D ) alpha smooth muscle actin (α-SMA), and ( E ) vimentin in liver sections of control and treated groups. No expression was observed in infected control and praziquantel (PZQ)-treated groups, whereas newly-formed liver-like cells in groups treated with Wharton’s jelly-derived mesenchymal stem cells (WJMSCs) showed positive expression (brown cytoplasmic discolouration) for AFP, CK-18, and Hep par-1. Positive expression of α-SMA and vimentin was observed only in scattered liver-like cells in groups treated with WJMSCs with the least expression observed in the groups which received WJMSCs combined with PZQ.

Article Snippet: Immunohistochemistry was performed by using an avidin-biotin complex immunoperoxidase technique with anti-human primary antibodies against alpha fetoprotein (AFP) (Cat. No. sc-51506, Santa Cruz Biotechnology, CA, USA) cytokeratin (CK)-7 (Cat. No. sc-17116, Santa Cruz Biotechnology, CA, USA), CK-18 (Cat. No. sc-6259, Santa Cruz Biotechnology, CA, USA), Hep par-1 (Cat. No. sc-58693, Santa Cruz Biotechnology, CA, USA), oval cell marker type 6 (OV-6) (Cat. No. MAB2020, R&D Systems, MN, USA), alpha smooth muscle actin (α-SMA) (Cat. No. M0851, Dako, CA, USA), and vimentin (Cat. No. sc-53464, Santa Cruz Biotechnology, CA, USA) diluted at 1:100, in PBS.

Techniques: Immunohistochemical staining, Staining, Control, Expressing, Infection, Derivative Assay

Journal: Scientific Reports

Article Title: Wharton’s jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni -induced liver fibrosis

doi: 10.1038/srep21005

Figure Lengend Snippet: Effects of treatment with Wharton’s jelly-derived mesenchymal stem cells (WJMSCs), given either alone or combined with praziquantel (PZQ), on the immunohistochemical expression of human ( A ) alpha fetoprotein (AFP), ( B ) cytokeratin-7 (CK-7), ( C ) CK-18, ( D ) Hep par-1, ( E ) oval cell marker type-6 (OV-6), ( F ) alpha smooth muscle actin (α-SMA), and ( G ) vimentin in the liver sections of mice infected with S. mansoni . WJMSCs (1.5 × 10 6 cells/mouse) were injected at either the 8 th (early) or 16 th (late) week (W) post infection. PZQ (500 mg/kg/day) was orally given at the 7 th W post infection for 2 consecutive days. Animals were sacrificed at the 10 th month post infection. Values are presented as means ± S.E. (n = 8–10). Significantly different (P < 0.05) £ versus WJMSCs (8W), @ versus WJMSCs (16W), and † versus PZQ + WJMSCs (8W). Statistical analysis was performed by one-way analysis of variance (One-way ANOVA) followed by Bonferroni post hoc test. O Significant interaction when PZQ and WJMSCs were combined using factorial design.

Article Snippet: Immunohistochemistry was performed by using an avidin-biotin complex immunoperoxidase technique with anti-human primary antibodies against alpha fetoprotein (AFP) (Cat. No. sc-51506, Santa Cruz Biotechnology, CA, USA) cytokeratin (CK)-7 (Cat. No. sc-17116, Santa Cruz Biotechnology, CA, USA), CK-18 (Cat. No. sc-6259, Santa Cruz Biotechnology, CA, USA), Hep par-1 (Cat. No. sc-58693, Santa Cruz Biotechnology, CA, USA), oval cell marker type 6 (OV-6) (Cat. No. MAB2020, R&D Systems, MN, USA), alpha smooth muscle actin (α-SMA) (Cat. No. M0851, Dako, CA, USA), and vimentin (Cat. No. sc-53464, Santa Cruz Biotechnology, CA, USA) diluted at 1:100, in PBS.

Techniques: Derivative Assay, Immunohistochemical staining, Expressing, Marker, Infection, Injection

Journal: Scientific Reports

Article Title: Wharton’s jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni -induced liver fibrosis

doi: 10.1038/srep21005

Figure Lengend Snippet: Effects of treatment with Wharton’s jelly-derived mesenchymal stem cells (WJMSCs), given either alone or combined with praziquantel (PZQ), on the gene expression of human ( A ) albumin (Alb) and ( B ) alpha fetoprotein (AFP) and murine ( C ) alpha smooth muscle actin (α-SMA), ( D ) collagen-I (Col-I), and ( E ) interleukin-13 (IL-13) in the liver tissue of mice infected with S. mansoni . WJMSCs (1.5 × 10 6 cells/mouse) were injected at either the 8 th (early) or 16 th (late) week (W) post infection. PZQ (500 mg/kg/day) was orally given at the 7 th W post infection for 2 consecutive days. Animals were sacrificed at the 10 th month post infection. Values are presented as means ± S.E. (n = 8-10). Significantly different (P < 0.05) * vs infected control, $ vs PZQ, £ vs WJMSCs (8W), @ vs WJMSCs (16W), and † vs PZQ + WJMSCs (8W). Statistical analysis was performed by one-way analysis of variance (One-way ANOVA) followed by Bonferroni post hoc test. O Significant interaction when PZQ and WJMSCs were combined using factorial design.

Article Snippet: Immunohistochemistry was performed by using an avidin-biotin complex immunoperoxidase technique with anti-human primary antibodies against alpha fetoprotein (AFP) (Cat. No. sc-51506, Santa Cruz Biotechnology, CA, USA) cytokeratin (CK)-7 (Cat. No. sc-17116, Santa Cruz Biotechnology, CA, USA), CK-18 (Cat. No. sc-6259, Santa Cruz Biotechnology, CA, USA), Hep par-1 (Cat. No. sc-58693, Santa Cruz Biotechnology, CA, USA), oval cell marker type 6 (OV-6) (Cat. No. MAB2020, R&D Systems, MN, USA), alpha smooth muscle actin (α-SMA) (Cat. No. M0851, Dako, CA, USA), and vimentin (Cat. No. sc-53464, Santa Cruz Biotechnology, CA, USA) diluted at 1:100, in PBS.

Techniques: Derivative Assay, Gene Expression, Infection, Injection, Control

Journal: Stem Cells International

Article Title: Electrical Stimulation Promotes Cardiac Differentiation of Human Induced Pluripotent Stem Cells

doi: 10.1155/2016/1718041

Figure Lengend Snippet: Characterisation of human iPSC line CERA007c6. Representative images showing expression of pluripotency markers (a) OCT4 and (b) TRA1-60 in the undifferentiated cells. CERA007c6 can be differentiated into all three lineages: (c) endoderm (alpha-fetoprotein, AFP), (d) mesoderm (smooth muscle actin, SMA), and ectoderm (Nestin). (f) An IgG negative control. Scale bar = 100 μ m.

Article Snippet: Immunocytochemistry is performed using the primary antibodies against alpha-fetoprotein (10 μ g/mL AFP, Millipore), alpha smooth muscle actin (10 μ g/mL, SMA, R&D Systems, MN, USA), and Nestin (10 μ g/mL, Abcam), followed by the Alexa Fluor-488 secondary antibody (10 μ g/mL; Invitrogen).

Techniques: Expressing, Negative Control

Journal: PLoS ONE

Article Title: Enhanced Hepatogenic Transdifferentiation of Human Adipose Tissue Mesenchymal Stem Cells by Gene Engineering with Oct4 and Sox2

doi: 10.1371/journal.pone.0108874

Figure Lengend Snippet: (A) The mRNA expression level of albumin (ALB) was strongly expressed in hepatogenically differentiated Oct4/Sox2-ATMSCs, whereas the expression level of α-fetoprotein (AFP) was lower than that of RFP-ATMSCs. The expression levels of transferrin were not significantly different in both cells. Undifferentiated ATMSCs and HepG2 were used as negative and positive controls, respectively. (B) Hepatocyte-like cells from RFP- and Oct4/Sox2-ATMSCs are confirmed by immunofluorescence staining for AFP and ALB. Nuclei were counterstained with Hoecst33342.

Article Snippet: The cells were incubated overnight sequentially at 4°C with primary antibodies raised against α-fetoprotein [(AFP) 1:50; goat, Santa Cruz] and albumin [(ALB) 1:50; mouse, Santa Cruz].

Techniques: Expressing, Immunofluorescence, Staining